Alkermes contributes to independent education by supporting educational grants. Our focus areas include educational activities with pragmatic approaches to improve patient care and public health in the domains of schizophrenia, depression, and alcohol and opioid dependence. We expect to contribute to a better and expanded understanding of the underlying mechanisms of disease and their relevance to medications that address those characteristics, as well as the overall treatment in a broad sense that includes psychosocial methods. Alkermes’ educational grant funds may not be used to support overhead expenses of the applicant or for any other institution affiliated with the applicant.
Areas of Interest
Substance Use Disorders
Major Depression Disorder (MDD)
Education grants will not be awarded to or for:
Alkermes is committed to complying with all applicable regulations and codes pertaining to education grants. Alkermes follows the requirements of the Compliance Program Guidance for Pharmaceutical Manufacturers issued by the Department of Health and Human Services Office of the Inspector General (“OIG Guidelines”), the Pharmaceutical Research and Manufacturers of America Code on Interactions with Healthcare Professionals (“PhRMA Code”), the FDA Guidance to Industry Supported Scientific and Educational Activities, and the Accreditation Council for Continuing Medical Education (“ACCME”) Standards for Commercial Support. Alkermes does not provide support for education programs that are intended to encourage, induce, or influence any grant recipient to purchase, prescribe, refer, recommend, sell, administer, or arrange for the purchase, sale or recommendation, or formulary placement of any Alkermes’ product.
To submit an education grant request, please register and submit your completed application and supporting documentation through Alkermes’ education grant management system located here.